Revisiting HBV resistance to entecavir with a phenotypic approach.
Adult
Aged
Amino Acid Substitution
Antiviral Agents
/ pharmacology
DNA, Viral
/ genetics
Drug Monitoring
Drug Resistance, Viral
/ genetics
Female
Genotype
Guanine
/ analogs & derivatives
Hepatitis B virus
/ drug effects
Hepatitis B, Chronic
/ virology
Humans
Male
Middle Aged
Mutation
Phenotype
Retrospective Studies
Treatment Failure
Antiviral
Entecavir
HBV
Phenotypic
Polymerase
Resistance
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
31
03
2020
revised:
30
05
2020
accepted:
01
07
2020
pubmed:
1
8
2020
medline:
13
7
2021
entrez:
1
8
2020
Statut:
ppublish
Résumé
Treatment adaptation after hepatitis B virus (HBV) treatment failure relies on genotypic resistance testing. However, the results of such tests are not always consistent with treatment response. These discrepancies may be due to differences in resistance levels between isolates with the same genotypic resistance testing profiles. We explored this hypothesis by investigating six cases of entecavir treatment failure with an integrative strategy combining genotypic and phenotypic resistance testing, medical record review and therapeutic drug monitoring. Among isolates with genotypic reduced susceptibility to entecavir, one displayed a higher level of resistance to entecavir (mean fold change in entecavir IC
Identifiants
pubmed: 32735901
pii: S0166-3542(20)30283-7
doi: 10.1016/j.antiviral.2020.104869
pii:
doi:
Substances chimiques
Antiviral Agents
0
DNA, Viral
0
entecavir
5968Y6H45M
Guanine
5Z93L87A1R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104869Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.